Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies.

Amino Acid Sequence Animals Disease Models, Animal Drug Design Humans Male Mice Oligopeptides / chemistry Pain / drug therapy Peptides / chemistry Protein Binding Receptors, Neurotensin / chemistry Receptors, Opioid, delta / agonists Receptors, Opioid, mu / agonists Structure-Activity Relationship

Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
12 11 2020
Historique:
pubmed: 10 9 2020
medline: 19 12 2020
entrez: 9 9 2020
Statut: ppublish

Résumé

Fusion of nonopioid pharmacophores, such as neurotensin, with opioid ligands represents an attractive approach for pain treatment. Herein, the μ-/δ-opioid agonist tetrapeptide H-Dmt-d-Arg-Aba-β-Ala-NH

Identifiants

DOI: 10.1021/acs.jmedchem.0c01376 PMID: 32902268 PMC: PMC7667639
pubmed: 32902268
doi: 10.1021/acs.jmedchem.0c01376
pmc: PMC7667639
doi:

Substances chimiques

KGNOP1 peptide 0
Oligopeptides 0
Peptides 0
Receptors, Neurotensin 0
Receptors, Opioid, delta 0
Receptors, Opioid, mu 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12929-12941

Subventions

Organisme : Austrian Science Fund FWF
ID : I 2463
Pays : Austria

Références

ChemMedChem. 2013 Jan;8(1):75-81
pubmed: 23097347
Bioorg Med Chem Lett. 2008 Mar 15;18(6):2013-8
pubmed: 18276136
J Biol Chem. 1973 Oct 10;248(19):6854-61
pubmed: 4745447
J Med Chem. 2012 Nov 26;55(22):9549-61
pubmed: 23102273
Eur J Pharmacol. 2019 Apr 5;848:80-87
pubmed: 30707956
Neuroscience. 2010 Mar 17;166(2):639-52
pubmed: 20035838
FASEB J. 2013 Sep;27(9):3741-52
pubmed: 23756650
Brain Res. 2010 Jan 13;1308:35-46
pubmed: 19874804
J Clin Invest. 2014 Mar;124(3):1199-213
pubmed: 24531547
Pain. 2017 Mar;158(3):505-515
pubmed: 28135212
Pain. 2018 Sep;159(9):1705-1718
pubmed: 29708942
J Med Chem. 2005 Oct 20;48(21):6523-43
pubmed: 16220969
Eur J Med Chem. 2019 Dec 1;183:111701
pubmed: 31550662
Brain Res. 2016 Oct 1;1648(Pt A):172-180
pubmed: 27473894
J Med Chem. 2015 Oct 8;58(19):7785-95
pubmed: 26348111
J Med Chem. 2018 Nov 8;61(21):9784-9789
pubmed: 30351003
Nat Struct Mol Biol. 2006 Sep;13(9):778-86
pubmed: 16906158
Biophys J. 2010 Dec 15;99(12):4037-46
pubmed: 21156147
Mol Pharmacol. 2001 Dec;60(6):1392-8
pubmed: 11723247
Br J Anaesth. 2019 Jun;122(6):e136-e145
pubmed: 31010646
Int J Pept Protein Res. 1993 Feb;41(2):181-4
pubmed: 8458692
Int J Pept Protein Res. 1994 Sep;44(3):233-8
pubmed: 7822099
Front Pharmacol. 2019 Apr 17;10:407
pubmed: 31057409
J Med Chem. 2016 Apr 28;59(8):3777-92
pubmed: 27035422
Behav Pharmacol. 2011 Sep;22(5-6):573-81
pubmed: 21691202
J Med Chem. 2019 Jan 24;62(2):420-444
pubmed: 30035545
J Biol Chem. 2000 Jan 7;275(1):328-36
pubmed: 10617622
Biol Psychiatry. 2020 Jan 1;87(1):15-21
pubmed: 31806082
ACS Med Chem Lett. 2019 May 10;10(6):960-965
pubmed: 31223455
J Med Chem. 2019 Jan 24;62(2):641-653
pubmed: 30571123
Arch Biochem Biophys. 2018 Dec 15;660:36-52
pubmed: 30342013
Eur J Pharmacol. 1991 Nov 26;205(2):191-8
pubmed: 1812009
J Pharmacol Exp Ther. 1981 Jun;217(3):645-51
pubmed: 6112261
J Pharmacol Exp Ther. 2019 Nov;371(2):396-408
pubmed: 31481516
Eur J Pharmacol. 2017 Jun 15;805:1-13
pubmed: 28341345
Nature. 2012 Oct 25;490(7421):508-13
pubmed: 23051748
Mol Pain. 2010 Dec 06;6:86
pubmed: 21134256
Methods Mol Med. 1999;23:321-38
pubmed: 21380905
Pharmacol Rep. 2013;65(4):836-46
pubmed: 24145077
J Med Chem. 2008 Mar 27;51(6):1610-6
pubmed: 18321036
ACS Chem Neurosci. 2016 Sep 21;7(9):1225-31
pubmed: 27359371
Eur J Pharmacol. 1992 Aug 25;219(2):327-9
pubmed: 1425958
Eur J Med Chem. 2015 Mar 6;92:64-77
pubmed: 25544687
J Med Chem. 2003 Sep 11;46(19):4141-8
pubmed: 12954066
Curr Pharm Des. 2013;19(42):7435-50
pubmed: 23448481
ACS Chem Neurosci. 2019 Nov 20;10(11):4535-4544
pubmed: 31589400
J Med Chem. 2018 Aug 23;61(16):7103-7115
pubmed: 30035538
Brain Res. 1991 Aug 23;557(1-2):227-35
pubmed: 1660754
J Med Chem. 2017 Apr 27;60(8):3303-3313
pubmed: 28368584
Trends Pharmacol Sci. 2014 Jul;35(7):308-16
pubmed: 24878326
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
pubmed: 4202581
J Neurochem. 2008 May;105(4):1100-14
pubmed: 18182046
Neuropharmacology. 1999 Jul;38(7):1027-34
pubmed: 10428421
Ann Intern Med. 2015 Feb 17;162(4):276-86
pubmed: 25581257
Eur J Pain. 2012 Apr;16(4):473-84
pubmed: 22396077
Eur J Pharmacol. 1979 Feb 15;54(1-2):129-39
pubmed: 421735
Molecules. 2020 Apr 29;25(9):
pubmed: 32365707
J Med Chem. 2014 Jun 26;57(12):5318-32
pubmed: 24856674

Auteurs

Simon Gonzalez (S)

Research Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium.

Maria Dumitrascuta (M)

Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria.

Emilie Eiselt (E)

Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, J1H 5N4 Sherbrooke, Canada.

Stevany Louis (S)

Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria.

Linda Kunze (L)

Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria.

Annalisa Blasiol (A)

Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria.

Mélanie Vivancos (M)

Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, J1H 5N4 Sherbrooke, Canada.

Santo Previti (S)

Research Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium.

Elke Dewolf (E)

Research Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium.

Charlotte Martin (C)

Research Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium.

Dirk Tourwé (D)

Research Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium.

Florine Cavelier (F)

Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, 34095 Montpellier, France.
ORCID: 0000-0001-5308-6416

Louis Gendron (L)

Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, J1H 5N4 Sherbrooke, Canada.
ORCID: 0000-0002-2058-8863

Philippe Sarret (P)

Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, J1H 5N4 Sherbrooke, Canada.
ORCID: 0000-0002-7627-701X

Mariana Spetea (M)

Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria.
ORCID: 0000-0002-2379-5358

Steven Ballet (S)

Research Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, 1050 Brussels, Belgium.
ORCID: 0000-0003-4123-1641

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Sciences de l'information › Sources d'information › Services d'information › Documentation › Données de séquences moléculaires › Séquence d'acides aminés › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Eucaryotes › Animaux › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Conception de médicament › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Sensation › Douleur › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur aux neuropeptides › Récepteur neurotensine › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur aux neuropeptides › Récepteurs aux opioïdes › Récepteur delta › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur aux neuropeptides › Récepteurs aux opioïdes › Récepteur mu › Optimized Opioid-Neurotensin Multitarget...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Optimized Opioid-Neurotensin Multitarget...